Activation-induced mast cell survival following IgECL in presence of ABT-737 and roscovitine.

Abstract

<p>(A) CBMC treated with 0.5 μM ABT-737 alone or in combination with 5 μM roscovitine following IgECL. N=6–3. (B) LAD-2 treated with 0.5 μM ABT-737 alone or in combination with 5 μM roscovitine following IgECL. N=3 Viability was assessed after 24 hrs using propidium iodide plus FITC-conjugated Annexin V. Change in viability is expressed as percentage viable cells after treatment deducted from untreated cells. ABT-737 = ABT, roscovitine = rosc.</p